The outbreak of the Ebola virus disease (EVD) in 2014 mobilized international efforts to contain a global health crisis. The emergence of the deadly virus in the United States and Europe among health care workers intensified fears of a worldwide epidemic. Market incentives for pharmaceutical firms to allocate their research and development resources toward Ebola treatments were weak because the limited number of EVD cases were previously confined to rural areas of West Africa. We discuss 3 policy recommendations to address the long-term challenges of EVD in an interconnected world. (AmJPublic Health. 2015;105:e8–e10. doi: 10.2105/AJPH.2015.302576) [ABSTRACT FROM AUTHOR]
© 2001-2024 Fundación Dialnet · Todos los derechos reservados